ERBB2 and triple-negative breast carcinoma: The log-rank test that included the one patient requiring special consideration of classification showed a significant difference (P < .01) in the post-diagnosis median survival time among the luminal breast cancer group (n = 11, 73.0 days, 95% CI, 37–139 days), triple-negative breast cancer group (n = 3, 36.0 days, 95% CI = 23–not available days), and HER2-positive group (n = 8, 165 days, 95% CI = 25–187 days).